CoChat
Sign Up
Cited by 48

The DOI matches its Crossref record.

Gene Therapy for Chronic Myelogenous Leukemia (CML): A Retroviral Vector That Renders Hematopoietic Progenitors Methotrexate-Resistant and CML Progenitors Functionally Normal and Nontumorigenic In Vivo

Zhao, Robert C.H., McIvor, R. Scott, Griffin, James D., Verfaillie, Catherine M.·1997·Blood
DOI 10.1182/blood.v90.12.4687
Open this paper in CoChat — free account

Abstract

Chronic myelogenous leukemia (CML) is a malignant disease of the human hematopoietic stem cell caused by the BCR/ABL gene rearrangement. The only curative therapy is allogeneic transplantation. Although autologous transplants may prolong survival, most patients relapse because of disease persisting in the host and in the graft. Continued administration of chemotherapy after transplant could reduce the incidence of relapse provided that the autograft can be protected by transfer of a drug-resistance gene. However, CML autografts will almost certainly contain malignant stem cells that will also be rendered drug-resistant. The presence of the BCR/ABL oncoprotein is necessary and sufficient for malignant transformation seen in CML. We thus hypothesized that transfer of a vector that combines a drug-resistance gene with anti-BCR/ABL antisense (AS) sequences may allow for posttransplant chemotherapy to decrease persistent disease while rendering inadvertently transduced CML stem and progenitor cells functionally normal. We constructed a retroviral vector, LasBD, that combines the methotrexate (MTX)-resistant tyrosine-22 dihydrofolate-reductase (tyr22-DHFR) gene and AS sequences directed at the b3a2 BCR/ABL breakpoint. b3a2 BCR/ABL containing 32D and MO7e cells were transduced with LasBD and selected in MTX for 14 days. Expression of the AS sequences reduced BCR/ABL mRNA and p210BCR/ABL protein levels by 6- to 10-fold in most cells. This subsequently led to the restoration of normal function of BCR/ABL cDNA+ cells: they grew significantly slower in the presence of interleukin-3 (IL-3); they underwent apoptotic cell death when cultured without IL-3; and they had restored expression and function of adhesion receptors. These effects were specific, because LasBD-containing AS sequences directed at the b3a2 BCR/ABL breakpoint did not affect p190BCR/ABL-containing cells. LasBD also rendered 20% to 30% of primary Ph− and Ph+ CD34+ cells MTX-resistant and decreased BCR/ABL mRNA levels in MTX resistant Ph+ CD34+ cells by 10-fold. Expression of the MTX-resistant DHFR gene and the AS sequences has been stable for at least 1 year in vitro and for more than 70 days in vivo. Finally, LasBD decreased tumorigenicity of 32DBCR/ABL cells in vivo by 3 to 4 logs. In conclusion, the tyr22-DHFR gene in the LasBD vector can protect normal hematopoietic cells from MTX-mediated toxicity, whereas the AS sequences in LasBD can suppress expression of the BCR/ABL gene and restore normal function of BCR/ABL cDNA-containing cells. The LasBD vector may therefore prove to be an extremely useful adjunct in autologous transplantation for CML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.v90.12.4687

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 41

  1. Fialkow, 1977, Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage., Am J Med, 63, 125, 10.1016/0002-9343(77)90124-3 · DOI
  2. Bartram, 1983, Translocation of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia., Nature, 306, 277, 10.1038/306277a0 · DOI
  3. Rowley, 1990, The Philadelphia chromosome translocation: A paradigm for understanding leukemia., Cancer, 65, 2178, 10.1002/1097-0142(19900515)65:10<2178::AID-CNCR2820651004>3.0.CO;2-# · DOI
  4. Daley, 1990, Induction of chronic myelogenous leukemia in mice by the P210BCR/ABL gene of the Philadelphia chromosome., Science, 247, 824, 10.1126/science.2406902 · DOI
  5. Gishizky, 1992, Initiation of dysregulated growth of multipotent progenitor cells by bcr-abl in vitro., Science, 256, 836, 10.1126/science.1375394 · DOI
  6. Snyder, 1990, Treatment of chronic myelogenous leukemia with bone marrow transplantation., Hematol Oncol Clin North Am, 4, 535, 10.1016/S0889-8588(18)30477-5 · DOI
  7. McGlave, 1993, Unrelated donor bone marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program., Blood, 81, 543, 10.1182/blood.V81.2.543.543 · DOI
  8. McGlave, 1994, Autologous transplant therapy for chronic myelogenous leukemia prolongs survival: Results from eight transplant centers., Lancet, 343, 1486, 10.1016/S0140-6736(94)92589-5 · DOI
  9. Deisseroth, 1994, Genetic marking shows that Ph+ cells present in autlogous marrow of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplants in CML., Blood, 83, 3068, 10.1182/blood.V83.10.3068.3068 · DOI
  10. Mackinnon, 1994, Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia., Blood, 83, 3409, 10.1182/blood.V83.11.3409.3409 · DOI
  11. Corey, 1990, Serial transplantation of MTX-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells., Blood, 75, 337, 10.1182/blood.V75.2.337.337 · DOI
  12. Vinh, 1993, Selective expression of drug-resistant dihydrofolate reductase activity in mice transduced with DHFR-retroviruses and administered methotrexate., J Pharm Exp Therapeutics, 267, 989
  13. Zhao, 1994, Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase., Cancer Gene Therapy, 1, 27
  14. May, 1995, Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity., Blood, 86, 2439, 10.1182/blood.V86.6.2439.bloodjournal8662439 · DOI
  15. Szczylik, 1991, Selective inhibition of leukemia cell proliferation by BCR-ABL anti-sense oligonucleotides., Science, 253, 562, 10.1126/science.1857987 · DOI
  16. Morris, 1994, Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. A variety of amino acid substitutions conferring methotrexate resistance., Biochem Pharmacol, 47, 1207, 10.1016/0006-2952(94)90393-X · DOI
  17. Braun, 1997, Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: A comparison of methotrexate resistance., Cancer Gene Ther, 4, 26
  18. Markowitz, 1988, A safe packaging line for gene transfer: Separating viral genes on two different plasmids., J Virol, 62, 1120, 10.1128/JVI.62.4.1120-1124.1988 · DOI
  19. Bauer, 1995, Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines by using retroviral vectors having a gibbon ape leukemia virus envelope., Blood, 86, 2379, 10.1182/blood.V86.6.2379.bloodjournal8662379 · DOI
  20. Miller, 1986, Redesign of retrovirus packaging lines to avoid recombination leading to helper virus production., Mol Cell Biol, 6, 2895, 10.1128/MCB.6.8.2895 · DOI
  21. Carlesso, 1994, Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line., Oncogene, 9, 149
  22. Orchard, 1993, Retroviral-mediated transfer of the murine interleukin-3 gene engineered for intracellular retention results in a myeloproliferative syndrome but is associated with circulating interleukin-3 levels., Exp Hematol, 21, 1245
  23. Sirard, 1994, Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism., Blood, 83, 1575, 10.1182/blood.V83.6.1575.1575 · DOI
  24. Verfaillie, 1996, BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients., Blood, 87, 4770, 10.1182/blood.V87.11.4770.bloodjournal87114770 · DOI
  25. Cortez, 1995, Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis., Mol Cell Biol, 15, 5531, 10.1128/MCB.15.10.5531 · DOI
  26. Goga, 1995, Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene., Cell, 82, 981, 10.1016/0092-8674(95)90277-5 · DOI
  27. Nieborowska-Skorska, 1994, The role of c-Myc protooncogene in chronic myelogenous leukemia., Folia Histochem Cytobiol, 32, 231
  28. Philpott, 1996, The use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques., Blood, 87, 2244, 10.1182/blood.V87.6.2244.bloodjournal8762244 · DOI
  29. Bi, 1994, The involvement of “tumor suppressor” p53 in normal and chronic myelogenous leukemia hemopoiesis., Cancer Res, 54, 582
  30. Sanchez-Garcia, 1995, Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2., Proc Natl Acad Sci USA, 92, 5287, 10.1073/pnas.92.12.5287 · DOI
  31. Gordon, 1984, Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myeloid leukaemia., Nature, 328, 342, 10.1038/328342a0 · DOI
  32. Verfaillie, 1997, Integrin-mediated regulation of hematopoiesis: Do BCR-ABL induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?, Acta Haematol, 97, 40, 10.1159/000203658 · DOI
  33. Verfaillie, 1992, Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV., J Clin Invest, 90, 1232, 10.1172/JCI115985 · DOI
  34. Bhatia, 1994, Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function., J Clin Invest, 94, 384, 10.1172/JCI117333 · DOI
  35. Ghaffari, 1995, Differentiation-associated changes in CD44 isoform expression during normal hematopoiesis and their alteration in chronic myeloid leukemia., Blood, 86, 2976, 10.1182/blood.V86.8.2976.2976 · DOI
  36. Renshaw, 1995, The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation., Mol Cell Biol, 15, 1286, 10.1128/MCB.15.3.1286 · DOI
  37. Eaves, 1986, Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells., Proc Natl Acad Sci USA, 83, 5306, 10.1073/pnas.83.14.5306 · DOI
  38. Allen, 1992, Philadelphia chromosome-positive leukaemia: The translocated genes and their gene products., Baill Clin Haematol, 5, 897, 10.1016/S0950-3536(11)80051-X · DOI
  39. Chen, 1996, Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia., Genes Chromosom Cancer, 15, 147, 10.1002/(SICI)1098-2264(199603)15:3<147::AID-GCC1>3.0.CO;2-2 · DOI
  40. Freier, 1986, Improved free-energy parameters for predictions of RNA duplex stability., Proc Natl Acad Sci USA, 83, 9373, 10.1073/pnas.83.24.9373 · DOI · Paper page
  41. Zuker, 1981, Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information., Nucleic Acids Res, 9, 133, 10.1093/nar/9.1.133 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zhao, R. C. H., McIvor, R. S., Griffin, J. D., & Verfaillie, C. M.
Venue
Blood
Publisher
American Society of Hematology
Published
1997-12-15
Volume
90
Issue
12
Pages
4687-4698
ISSN
  • 1528-0020
  • 0006-4971
DOI
10.1182/blood.v90.12.4687
Cited by
48
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review